Top

Published in:

Open Access 01-12-2024 | Osimertinib | Research

Aberrant expression of MRAS and HEG1 as the biomarkers for osimertinib resistance in LUAD

Authors: Mingxin Liu, Bo Tang, Run Xiang, Peihong Hu, Chuan Xu, Lanlin Hu, Qiang Li

Published in: Discover Oncology | Issue 1/2024

Abstract

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the most applied targeted therapy for EGFR-mutant lung adenocarcinoma (LUAD). The third-generation EGFR-TKI, osimertinib, is widely used throughout lung cancer treatment, with single or combination modes. One of the main barriers in osimertinib treatment is the acquired resistance and mechanisms are not fully understood. Gene expression other than genetic mutations might predict drug response and mediate resistance occurrence. We analyzed six datasets of osimertinib-resistant LUAD cells from the Gene Expression Omnibus (GEO) database and identified two hub genes, named MRAS and HEG1. We found that the expression mode of MRAS/HEG1 in LUAD was osimertinib-dependent and contributed to drug resistance. We also explored potential mechanisms of hub genes related osimertinib resistance and emphasized the M2 infiltration involved. Moreover, potential therapeutic agents conquering MRAS/HEG1-related resistance were also identified. In conclusion, MRAS and HEG1 might be responsible for osimertinib resistance and could be promising prognostic biomarkers for osimertinib response in LUAD, which might provide insights into therapeutic strategies.

Available only for authorised users

Li C, Lei S, Ding L, Xu Y, Wu X, Wang H, Zhang Z, Gao T, Zhang Y, Li L. Global burden and trends of lung cancer incidence and mortality. Chin Med J (Engl). 2023;136:1583–90. https://doi.org/10.1097/CM9.0000000000002529.CrossRefPubMed

Gomatou G, Syrigos N, Kotteas E. Osimertinib resistance: molecular mechanisms and emerging treatment options. Cancers (Basel). 2023. https://doi.org/10.3390/cancers15030841.CrossRefPubMed

Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun (Lond). 2022;42:937–70. https://doi.org/10.1002/cac2.12359.CrossRefPubMed

Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020;61:167–79. https://doi.org/10.1016/j.semcancer.2019.09.015.CrossRefPubMedPubMedCentral

Takeda M, Nakagawa K. First- and second-generation EGFR-TKIs are all replaced to osimertinib in chemo-naive EGFR mutation-positive non-small cell lung cancer? Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20010146.CrossRefPubMedPubMedCentral

Singh S, Sadhukhan S, Sonawane A. 20 Years since the approval of first EGFR-TKI, gefitinib: insight and foresight. Biochim Biophys Acta Rev Cancer. 2023;1878: 188967. https://doi.org/10.1016/j.bbcan.2023.188967.CrossRefPubMed

Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21:560–2. https://doi.org/10.1038/nm.3854.CrossRefPubMedPubMedCentral

Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 2018;4:1527–34. https://doi.org/10.1001/jamaoncol.2018.2969.CrossRefPubMed

Chmielecki J, Gray JE, Cheng Y, Ohe Y, Imamura F, Cho BC, Lin MC, Majem M, Shah R, Rukazenkov Y, Todd A, Markovets A, Barrett JC, Hartmaier RJ, Ramalingam SS. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nat Commun. 2023;14(1):1070. https://doi.org/10.1038/s41467-023-35961-y.CrossRefPubMedPubMedCentral

10.

Nukaga S, Yasuda H, Tsuchihara K, Hamamoto J, Masuzawa K, Kawada I, Naoki K, Matsumoto S, Mimaki S, Ikemura S, Goto K, Betsuyaku T, Soejima K. Amplification of EGFR wild-type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors. Cancer Res. 2017;77(8):2078–89. https://doi.org/10.1158/0008-5472.CrossRefPubMed

11.

Hayakawa D, Takahashi F, Mitsuishi Y, Tajima K, Hidayat M, Winardi W, Ihara H, Kanamori K, Matsumoto N, Asao T, Ko R, Shukuya T, Takamochi K, Hayashi T, Suehara Y, Takeda Nakamura I, Ueno T, Kohsaka S, Mano H, Takahashi K. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation. Thorac Cancer. 2020;11(1):140–9. https://doi.org/10.1111/1759-7714.13255.CrossRefPubMed

12.

Lin Z, Li J, Zhang J, Feng W, Lu J, Ma X, Ding W, Ouyang S, Lu J, Yue P, et al. Metabolic reprogramming driven by IGF2BP3 promotes acquired resistance to EGFR Inhibitors in non-small cell lung cancer. Cancer Res. 2023;83:2187–207. https://doi.org/10.1158/0008-5472.CAN-22-3059.CrossRefPubMed

13.

Han R, Guo H, Shi J, Wang H, Zhao S, Jia Y, Liu X, Li J, Cheng L, Zhao C, Li X, Zhou C. Tumour microenvironment changes after osimertinib treatment resistance in non-small cell lung cancer. Eur J Cancer. 2023;189: 112919. https://doi.org/10.1016/j.ejca.2023.05.00.CrossRefPubMed

14.

Thorsson V, Gibbs DL, Brown SD, Shmulevich I. The immune landscape of cancer. Immunity. 2018;48(4):812–30. https://doi.org/10.1016/j.immuni.2018.03.023.CrossRefPubMedPubMedCentral

15.

Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022;15:173. https://doi.org/10.1186/s13045-022-01391-4.CrossRefPubMedPubMedCentral

16.

Passaro A, Jänne PA, Mok T, et al. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2021;2:377–91. https://doi.org/10.1038/s43018-021-00195-8.CrossRefPubMed

17.

Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–40. https://doi.org/10.1093/bioinformatics/btp616.CrossRefPubMed

18.

Taminau J, Meganck S, Lazar C, Steenhoff D, Coletta A, Molter C, Duque R, de Schaetzen V, WeissSolis DY, Bersini H, et al. Unlocking the potential of publicly available microarray data using inSilicoDb and inSilicoMerging R/Bioconductor packages. BMC Bioinform. 2012;13:335. https://doi.org/10.1186/1471-2105-13-335.CrossRef

19.

Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8:118–27. https://doi.org/10.1093/biostatistics/kxj037.CrossRefPubMed

20.

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. https://doi.org/10.1186/s13059-014-0550-8.CrossRefPubMedPubMedCentral

21.

Maeser D, Gruener RF, Huang RS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021. https://doi.org/10.1093/bib/bbab260.CrossRefPubMedPubMedCentral

22.

Tumeh PC, Harview CL, Yearley JH, Ribas A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71. https://doi.org/10.1038/nature13954.CrossRefPubMedPubMedCentral

23.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–25. https://doi.org/10.1056/NEJMoa1713137.CrossRefPubMed

24.

Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022;19:499–514. https://doi.org/10.1038/s41571-022-00639-9.CrossRefPubMedPubMedCentral

25.

Koulouris A, Tsagkaris C, Corriero AC, Metro G, Mountzios G. Resistance to TKIs in EGFR-mutated non-small cell lung cancer: from mechanisms to new therapeutic strategies. Cancers (Basel). 2022. https://doi.org/10.3390/cancers14143337.CrossRefPubMed

26.

Li S, Zhu S, Wei H, Zhu P, Jiao Y, Yi M, Gong J, Zheng K, Zhang L. The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC. Biomed Pharmacother. 2022;156: 113959. https://doi.org/10.1016/j.biopha.2022.113959.CrossRefPubMed

27.

Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29:i10–9. https://doi.org/10.1093/annonc/mdx703.CrossRefPubMedPubMedCentral

28.

Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046–61. https://doi.org/10.1158/2159-8290.CD-14-0337.CrossRefPubMedPubMedCentral

29.

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41–50. https://doi.org/10.1056/NEJMoa1913662.CrossRefPubMed

30.

Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629–40. https://doi.org/10.1056/NEJMoa1612674.CrossRefPubMed

31.

Nagasaka M, Zhu VW, Lim SM, Greco M, Wu F, Ou SI. Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC. J Thorac Oncol. 2021;16:740–63. https://doi.org/10.1016/j.jtho.2020.11.028.CrossRefPubMed

32.

Zalaquett Z, Catherine Rita Hachem M, Kassis Y, Hachem S, Eid R, Raphael Kourie H, Planchard D. Acquired resistance mechanisms to osimertinib: the constant battle. Cancer Treat Rev. 2023;116: 102557. https://doi.org/10.1016/j.ctrv.2023.102557.CrossRefPubMed

33.

Du X, Yang B, An Q, Assaraf YG, Cao X, Xia J. Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. Innovation (Camb). 2021;2: 100103. https://doi.org/10.1016/j.xinn.2021.100103.CrossRefPubMed

34.

Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018;17:53. https://doi.org/10.1186/s12943-018-0793-1.CrossRefPubMedPubMedCentral

35.

Liu L, You L, Tan L, Wang DW, Cui W. Genetic insight into the role of MRAS in coronary artery disease risk. Gene. 2015;564:63–6. https://doi.org/10.1016/j.gene.2015.03.041.CrossRefPubMed

36.

Smith SB, Parisien M, Bair E, Belfer I, Chabot-Dore AJ, Gris P, Khoury S, Tansley S, Torosyan Y, Zaykin DV, et al. Genome-wide association reveals contribution of MRAS to painful temporomandibular disorder in males. Pain. 2019;160:579–91. https://doi.org/10.1097/j.pain.0000000000001438.CrossRefPubMed

37.

Yasumoto M, Sakamoto E, Ogasawara S, Isobe T, Kizaki J, Sumi A, Kusano H, Akiba J, Torimura T, Akagi Y, et al. Muscle RAS oncogene homolog (MRAS) recurrent mutation in Borrmann type IV gastric cancer. Cancer Med. 2017;6:235–44. https://doi.org/10.1002/cam4.959.CrossRefPubMed

38.

Suzuki H, Takenouchi T, Uehara T, Takasago S, Ihara S, Yoshihashi H, Kosaki K. Severe Noonan syndrome phenotype associated with a germline Q71R MRAS variant: a recurrent substitution in RAS homologs in various cancers. Am J Med Genet A. 2019;179:1628–30. https://doi.org/10.1002/ajmg.a.61261.CrossRefPubMed

39.

Adachi Y, Kimura R, Hirade K, Yanase S, Nishioka Y, Kasuga N, Yamaguchi R, Ebi H. Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS. Nat Cancer. 2023;4:829–43. https://doi.org/10.1038/s43018-023-00575-2.CrossRefPubMed

40.

Ward KR, Zhang KX, Somasiri AM, Roskelley CD, Schrader JW. Expression of activated M-Ras in a murine mammary epithelial cell line induces epithelial-mesenchymal transition and tumorigenesis. Oncogene. 2004;23:1187–96. https://doi.org/10.1038/sj.onc.1207226.CrossRefPubMed

41.

Kimmelman AC, Osada M, Chan AM. R-Ras3, a brain-specific Ras-related protein, activates Akt and promotes cell survival in PC12 cells. Oncogene. 2000;19:2014–22. https://doi.org/10.1038/sj.onc.1203530.CrossRefPubMed

42.

Yoshikawa Y, Satoh T, Tamura T, Wei P, Bilasy SE, Edamatsu H, Aiba A, Katagiri K, Kinashi T, Nakao K, et al. The M-Ras-RA-GEF-2-Rap1 pathway mediates tumor necrosis factor-alpha dependent regulation of integrin activation in splenocytes. Mol Biol Cell. 2007;18:2949–59. https://doi.org/10.1091/mbc.e07-03-0250.CrossRefPubMedPubMedCentral

43.

Rodriguez-Viciana P, Oses-Prieto J, Burlingame A, Fried M, McCormick F. A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. Mol Cell. 2006;22:217–30. https://doi.org/10.1016/j.molcel.2006.03.027.CrossRefPubMed

44.

Young LC, Hartig N, Munoz-Alegre M, Oses-Prieto JA, Durdu S, Bender S, Vijayakumar V, Vietri Rudan M, Gewinner C, Henderson S, et al. An MRAS, SHOC2, and SCRIB complex coordinates ERK pathway activation with polarity and tumorigenic growth. Mol Cell. 2013;52:679–92. https://doi.org/10.1016/j.molcel.2013.10.004.CrossRefPubMed

45.

Castro AF, Campos T, Babcock JT, Armijo ME, Martinez-Conde A, Pincheira R, Quilliam LA. M-Ras induces Ral and JNK activation to regulate MEK/ERK-independent gene expression in MCF-7 breast cancer cells. J Cell Biochem. 2012;113:1253–64. https://doi.org/10.1002/jcb.23458.CrossRefPubMedPubMedCentral

46.

Zhao A, Li D, Mao X, Yang M, Deng W, Hu W, Chen C, Yang G, Li L. GNG2 acts as a tumor suppressor in breast cancer through stimulating MRAS signaling. Cell Death Dis. 2022;13:260. https://doi.org/10.1038/s41419-022-04690-3.CrossRefPubMedPubMedCentral

47.

Mably JD, Mohideen MA, Burns CG, Chen JN, Fishman MC. heart of glass regulates the concentric growth of the heart in zebrafish. Curr Biol. 2003;13:2138–47. https://doi.org/10.1016/j.cub.2003.11.055.CrossRefPubMed

48.

de Kreuk BJ, Gingras AR, Knight JD, Liu JJ, Gingras AC, Ginsberg MH. Heart of glass anchors Rasip1 at endothelial cell-cell junctions to support vascular integrity. Elife. 2016;5: e11394. https://doi.org/10.7554/eLife.11394.CrossRefPubMedPubMedCentral

49.

Zhao YR, Wang JL, Xu C, Li YM, Sun B, Yang LY. HEG1 indicates poor prognosis and promotes hepatocellular carcinoma invasion, metastasis, and EMT by activating Wnt/beta-catenin signaling. Clin Sci (Lond). 2019;133:1645–62. https://doi.org/10.1042/CS20190225.CrossRefPubMed

50.

Shi Y, Niu Y, Yuan Y, Li K, Zhong C, Qiu Z, Li K, Lin Z, Yang Z, Zuo D, et al. PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer. Nat Commun. 1932;2023:14. https://doi.org/10.1038/s41467-023-37542-5.CrossRef

51.

Hou H, Sun D, Zhang C, Liu D, Zhang X. ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non-small cell lung cancer. Thorac Cancer. 2021;12:962–9. https://doi.org/10.1111/1759-7714.13817.CrossRefPubMedPubMedCentral

52.

Murakami Y, Kusakabe D, Watari K, Kawahara A, Azuma K, Akiba J, Taniguchi M, Kuwano M, Ono M. AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer. Sci Rep. 2022;12:8983. https://doi.org/10.1038/s41598-022-12995-8.CrossRefPubMedPubMedCentral

53.

Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, et al. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:4609–15. https://doi.org/10.1200/JCO.2010.30.5474.CrossRefPubMedPubMedCentral

54.

Nie M, Chen N, Pang H, Jiang T, Jiang W, Tian P, Yao L, Chen Y, DeBerardinis RJ, Li W, et al. Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse. J Clin Invest. 2022. https://doi.org/10.1172/JCI160152.CrossRefPubMedPubMedCentral

55.

Eberlein CA, Stetson D, Markovets AA, Al-Kadhimi KJ, Lai Z, Fisher PR, Meador CB, Spitzler P, Ichihara E, Ross SJ, et al. Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res. 2015;75:2489–500. https://doi.org/10.1158/0008-5472.CAN-14-3167.CrossRefPubMedPubMedCentral

56.

Higgins EM, Bos JM, Mason-Suares H, Tester DJ, Ackerman JP, MacRae CA, Sol-Church K, Gripp KW, Urrutia R, Ackerman MJ. Elucidation of MRAS-mediated Noonan syndrome with cardiac hypertrophy. JCI Insight. 2017;2: e91225. https://doi.org/10.1172/jci.insight.91225.CrossRefPubMedPubMedCentral

Title: Aberrant expression of MRAS and HEG1 as the biomarkers for osimertinib resistance in LUAD
Authors: Mingxin Liu
Bo Tang
Run Xiang
Peihong Hu
Chuan Xu
Lanlin Hu
Qiang Li
Publication date: 01-12-2024
Publisher: Springer US
Keywords: Osimertinib
Biomarkers
Published in: Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-024-01552-6

The potential clinical value of platelet aggregation in colorectal tumor progression

Open Access
Colorectal Cancer
Research

Pan-cancer analysis of COL15A1: an immunological and prognostic biomarker

Open Access
Research

Identification of GPNMB in endometrial cancer based on pan-cancer analysis and in vitro validation

Open Access
Endometrial Cancer
Research

Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study

Open Access
Tyrosine Kinase Inhibitors
Clinical Trial

Exploring the heterogeneity of interstitial cells of Cajal and their properties in gastrointestinal mesenchymal tumors applying single-cell RNA sequencing analysis

Open Access
Gastrointestinal Stromal Tumor
Analysis

A comparative study of ProGRP and CEA as serological markers in small cell lung cancer treatment

Open Access
SCLC
Research

Keynote webinar | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now

Keynote webinar | Spotlight on adolescent vaping

Live
Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET

Prof. Ann McNeill

Dr. Debbie Robson

Benji Horwell

Developed by: Springer Medicine

Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty in Geriatric Patients
On-demand webinar

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft

Prof. Barbara C. van Munster

Prof. Mirko Petrovic

Developed by: Springer Medicine

Watch now

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote series | Spotlight on menopause

Springer Medicine

Aberrant expression of MRAS and HEG1 as the biomarkers for osimertinib resistance in LUAD

Abstract

Other articles of this Issue 1/2024

The potential clinical value of platelet aggregation in colorectal tumor progression

Pan-cancer analysis of COL15A1: an immunological and prognostic biomarker

Identification of GPNMB in endometrial cancer based on pan-cancer analysis and in vitro validation

Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study

Exploring the heterogeneity of interstitial cells of Cajal and their properties in gastrointestinal mesenchymal tumors applying single-cell RNA sequencing analysis

A comparative study of ProGRP and CEA as serological markers in small cell lung cancer treatment

Keynote webinar | Spotlight on menopause

Keynote webinar | Spotlight on adolescent vaping

Keynote webinar | Spotlight on modern management of frailty

A quick guide to ECGs

At a glance: The STEP trials

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Please log in to get access to this content